As of 19 Nov 2026, CataX AI has raised $6.0M across 1 verified round on record (amounts in other currencies converted to USD); latest: 4000万元人民币 seed round, announced 16 Nov 2026.
A clinical-development entrant with an asset ownership model
catax.bioShanghai, ChinaBiotechFounded 2026
6 sources · checked 4 times, last 11h ago
Source 1 says the amount was not disclosed; the more specific contemporaneous reports in Sources 2–4 state the financing amount, so those reports prevail.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Seed | $6.0M 4000万元人民币 | 2026-11-16 | not stated | No recent discussion |
6 sources · checked 4 times, last 11h ago [ VERIFIED · CORRECTED ] read against 4 of 6 sources Source 1 says the amount was not disclosed; the more specific contemporaneous reports in Sources 2–4 state the financing amount, so those reports prevail. | ||||
2 people on 6 outlets
Found on X with Firecrawl search
CataX AI is an AI-native biotech that acquires or co-develops preclinical and early-clinical drug assets and uses AI agents with clinical experts to move them toward human proof of concept.
CataX is betting that the bottleneck in drug development has moved downstream from target and molecule discovery to clinical development: the coverage says early discovery represents about 20% of a new drug’s cost and time, with the remaining 80% in clinical development, while CataX describes a growing candidate backlog against limited clinical capacity. Its exclusive 4000万元人民币 seed investment from Qiming Venture Partners backs a Clinical-of-One model in which one clinical lead coordinates AI agents and external experts to select assets, generate human proof of concept and seek partners for further development.
Checked against 8 sources 3d ago